+34 697 878 137
Ibrutinib for patients with rituximab-refractory Waldenström’s macroglobulinaemia (iNNOVATE)

Ibrutinib for patients with rituximab-refractory Waldenström’s macroglobulinaemia (iNNOVATE)

ARTICLE

Authors: Meletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, Jeffrey V Matous, David Macdonald, Constantine Tam, Olivier Tournilhac, Shuo Ma, Albert Oriol, Leonard T Heffner, Chaim Shustik, Ramón García-Sanz, Robert F Cornell, Carlos Fernández de Larrea, Jorge J Castillo, Miquel Granell, Marie-Christine Kyrtsonis, Veronique Leblond, Argiris Symeonidis, Efstathios Kastritis, Priyanka Singh, Jianling Li, Thorsten Graef, Elizabeth Bilotti, Steven Treon, Christian Buske. On behalf of the iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia.

Published: December 9, 2016 / LANCET ONCOLOGY

Check out the paper here

VIDEO ABSTRACT

Production Company: In Motion Science / 2017

About the Author

Leave a Reply